Champions Oncology Inc (CSBR): Analyst Median Target

Symbol and logo of brand Champions Oncology Corp (CSBR)

The market dynamics of Champions Oncology (CSBR) on the GURU.Markets platform show figures at 12.01, while the business relies on TumorGraft, a system for personalized oncology therapy selection. Stable management under Joel Beckerman is developing data services, strengthening confidence through effective unit economics. However, Champions Oncology (CSBR) must compete for pharma contracts against AI platforms capable of replacing physical tests.

Champions Oncology Inc - CSBR Price Target Chart (period 07/04/2022 - 11/12/2026)

Analytical breakdowns for Champions Oncology (CSBR)

- market price and analyst price targets:
Stock Quotes championsoncology.com|CSBR - Price Target Chart
- stock exchange capitalization data:
Market Capitalization Champions Oncology Corp|CSBR - Enterprise Value
- company book value details:
Net Assets per Single Share Champions Oncology|CSBR - Company Book Value|Market Value to Book Value championsoncology.com|CSBR - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Champions Oncology|CSBR - Long-Term Debt to Capital|Short-Term Debt to Capital championsoncology.com|CSBR - Company Debts|Debt to Book Value Ratio Champions Oncology Corp|CSBR - Company Long-Term Debts|Company Current Liabilities Champions Oncology|Immediate Liquidity championsoncology.com
- financial results and valuation multiples details:
CSBR - Company Net Income|Expected Net Income Champions Oncology|CSBR - Price to Earnings Ratio|Future Price to Earnings Multiple championsoncology.com|CSBR - PEG Multiple|Enterprise Value to EBITDA Ratio Champions Oncology Corp|CSBR - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) Champions Oncology|CSBR - Earnings per share for the last twelve months|Year-over-year earnings per one share growth for the last 12 months championsoncology.com|CSBR - Earnings growth in current year|Expected net earnings per share growth next year Champions Oncology
Fundamental company analysis:Champions Oncology Inc (CSBR)
Original product of Champions Oncology

The scaling of IT platforms and the Lumin base for biopharmaceuticals directly impacts the median analyst price target, which synthesizes independent assessments of the fundamental value of Champions Oncology (CSBR). This indicator measures market expectations for the company's expansion, allowing investors to evaluate how strategic successes are discounted into the asset price, although general market risks continue to influence final portfolio returns.

Competing companies

Consensus Target beigene.com ONC|Price Target Chart Halozyme HALO|Analyst Median Target Revolution Medicines Inc (RVMD)|Ascentage - Analyst Consensus Forecast|CGON: Price Target Chart|UroGen Pharma Ltd. (URGN) - Price Target Chart|bicara.com - Fair Value Consensus|PSNL (Personalis) - Analyst Consensus Forecast|Consensus Target Erasca Inc (ERAS)|Analyst Consensus Forecast DCTH|Analyst Consensus Forecast Y-mAbs Corp (YMAB)|Price Target Chart Aura Biosciences, Inc. AURA|CADL: Broker Consensus Forecast|Accuray - Analyst Consensus Forecast|SELLAS Life Sciences (SLS) - Consensus Target|ACTU: Analyst Consensus Forecast|Average Forecast Price Citius Oncology Inc (CTOR)|Price Target Chart TuHURA Biosciences Inc.|TARA: Fair Value Consensus|Consensus Target FATE (Fate Therapeutics)|WHWK (aadibio.com) - Fair Value Consensus|Analyst Consensus Forecast TCRX (TScan Therapeutics, Inc.)|XBIT - Consensus Target|CVM: Consensus Target|OSTX - Analyst Consensus Forecast|Radiopharm Theranostics Limited (RADX) - Price Target Chart|Artiva Biotherapeutics - Fair Value Consensus|ANL (Adlai Nortye Ltd) - Analyst Consensus Forecast|Average Forecast Price Veru Corporation VERU|Analyst Consensus Forecast TPST|Consensus Target xiliotx.com XLO|Analyst Consensus Forecast RENB (Renovaro)|Fair Value Consensus MURA|Kairos Pharma Inc - Analyst Consensus Forecast|OKUR - Analyst Consensus Forecast|w2.cytomed.sg (GDTC) - Price Target Chart|Consensus Target Curis|Price Target Chart Apollomics Inc.|Tharimmune Inc - Forecast Levels Chart|Analyst Consensus Forecast ADVB|Analyst Median Target Genprex Inc|Price Target Chart Calidi Biotherapeutics, Inc. CLDI|Sunshine Biopharma Inc. (SBFM) - Average Forecast Price|XBIO - Price Target Chart|SLRX (Salarius Pharmaceuticals Inc) - Broker Consensus Forecast|Purple Biotech Corp (PPBT) - Price Target Chart|AONC - Analyst Median Target|Consensus Target BGNE|CKPT: Fair Value Consensus|Price Target Chart Elevation Oncology, Inc. (ELEV)|ICAD - Average Forecast Price|Price Target Chart Ikena Oncology IKNA|NTBL: Broker Consensus Forecast|Viracta - Analyst Consensus Forecast|morphosys.com (MOR) - Consensus Target|NAYA Biosciences Inc. (NAYA) - Price Target Chart|Average Forecast Price Ascentage Pharma Group International (AAPGV)